Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KALV 
Kalvista Pharmaceuticals Inc (KALV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: KALV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.78
1 Year Target Price $30.78
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.47% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 555.76M USD | Price to earnings Ratio - | 1Y Target Price 30.78 |
Price to earnings Ratio - | 1Y Target Price 30.78 | ||
Volume (30-day avg) 10 | Beta -0.15 | 52 Weeks Range 7.30 - 17.28 | Updated Date 10/24/2025 |
52 Weeks Range 7.30 - 17.28 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4138.08% |
Management Effectiveness
Return on Assets (TTM) -60.98% | Return on Equity (TTM) -190.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 408324469 | Price to Sales(TTM) 389.73 |
Enterprise Value 408324469 | Price to Sales(TTM) 389.73 | ||
Enterprise Value to Revenue 286.34 | Enterprise Value to EBITDA -3.53 | Shares Outstanding 50523274 | Shares Floating 28310211 |
Shares Outstanding 50523274 | Shares Floating 28310211 | ||
Percent Insiders 1.3 | Percent Institutions 111.65 |
Upturn AI SWOT
Kalvista Pharmaceuticals Inc
Company Overview
History and Background
KalVista Pharmaceuticals Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel, small molecule protease inhibitors to treat diseases with significant unmet needs. Founded in 2011, it has primarily focused on hereditary angioedema (HAE) and diabetic macular edema (DME).
Core Business Areas
- Hereditary Angioedema (HAE): Development of oral therapies for on-demand treatment and prophylactic prevention of HAE attacks.
- Small Molecule Protease Inhibitors: Discovery and development of novel small molecule protease inhibitors for various diseases.
Leadership and Structure
KalVista has a management team led by a CEO and is structured with departments focusing on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Seberutinib: An oral plasma kallikrein inhibitor in clinical development for the treatment of HAE attacks. There are no competitors with the same oral on-demand small molecule inhibitor. Main competitors are CSL Behring's Haegarda and Takeda's Takhzyro, which are injectables. Market share data is unavailable at this clinical trial phase; future revenue potential is significant assuming success in trials and approval.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments in research and development. The HAE market is a growing area with unmet needs for convenient oral therapies.
Positioning
KalVista is positioned as an innovator focusing on oral therapies for HAE, aiming to provide a convenient alternative to existing injectable treatments. The Company has a competitive advantage due to its novel approach for oral on-demand treatment.
Total Addressable Market (TAM)
The HAE market is estimated to be in billions of USD globally. KalVista is positioned to capture a significant share of this TAM with its oral therapy if approved. The total addressable market is approximately $2.5 billion.
Upturn SWOT Analysis
Strengths
- Novel oral therapy approach for HAE
- Strong intellectual property position
- Experienced management team
- Focused pipeline on specific unmet medical needs
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercial infrastructure
- Competition from established injectable therapies
- High cash burn rate for R&D
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other indications for protease inhibitors
- Positive clinical trial data leading to regulatory approval
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new and existing therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- TAK (TAK)
Competitive Landscape
KalVista aims to differentiate itself with an oral therapy alternative to the injectable treatments offered by CSL and Takeda. The competitive landscape is shifting with potential for oral therapies to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by the advancement of the pipeline, but is still considered to be limited at this stage.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include advancing seberutinib through clinical trials and exploring potential partnerships.
Summary
KalVista is a development-stage pharmaceutical company with a focus on oral therapies for HAE, particularly seberutinib. The company's success hinges on positive clinical trial outcomes and securing partnerships for commercialization. While an innovative approach gives KalVista a competitive edge, the company needs to watch out for clinical trial setbacks and competition from established treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kalvista Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-09 | CEO & Director Mr. Benjamin L. Palleiko | ||
Sector Healthcare | Industry Biotechnology | Full time employees 270 | Website https://www.kalvista.com |
Full time employees 270 | Website https://www.kalvista.com | ||
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.